{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Moderna+mRNA-1273", "query": { "intervention": "Moderna mRNA-1273" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 42, "total_pages": 5, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Moderna+mRNA-1273&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-08T11:31:18.226Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05119855", "title": "Safety and Immunogenicity of 9-valent Human Papillomavirus (9vHPV) Vaccine Coadministered With Messenger Ribonucleic Acid (mRNA)-1273 Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) (COVID-19) Vaccine (V503-076)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Papillomavirus Infections", "Coronavirus Disease (COVID-19)" ], "interventions": [ { "name": "9vHPV Vaccine", "type": "BIOLOGICAL" }, { "name": "mRNA-1273 Vaccine", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "9 Years", "maximum_age": "11 Years", "sex": "ALL", "summary": "9 Years to 11 Years" }, "enrollment_count": 165, "start_date": "2022-03-28", "completion_date": "2023-12-12", "has_results": true, "last_update_posted_date": "2026-02-05", "last_synced_at": "2026-09-08T11:31:18.226Z", "location_count": 38, "location_summary": "Phoenix, Arizona • Tucson, Arizona • Jonesboro, Arkansas + 33 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Jonesboro", "state": "Arkansas" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Bellflower", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05119855" }, { "nct_id": "NCT04889209", "title": "Delayed Heterologous SARS-CoV-2 Vaccine Dosing (Boost) After Receipt of EUA Vaccines", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "COVID-19" ], "interventions": [ { "name": "Ad26.COV2.S", "type": "BIOLOGICAL" }, { "name": "BNT162b2", "type": "BIOLOGICAL" }, { "name": "mRNA-1273", "type": "BIOLOGICAL" }, { "name": "mRNA-1273.211", "type": "BIOLOGICAL" }, { "name": "mRNA-1273.222", "type": "BIOLOGICAL" }, { "name": "SARS-CoV-2 rS/M1", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 867, "start_date": "2021-05-28", "completion_date": "2023-06-16", "has_results": true, "last_update_posted_date": "2025-04-20", "last_synced_at": "2026-09-08T11:31:18.226Z", "location_count": 10, "location_summary": "Decatur, Georgia • Baltimore, Maryland • New York, New York + 6 more", "locations": [ { "city": "Decatur", "state": "Georgia" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "New York", "state": "New York" }, { "city": "Rochester", "state": "New York" }, { "city": "Cincinnati", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT04889209" }, { "nct_id": "NCT05321407", "title": "COVID-19 Vaccine Responses in PIDD Subjects", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "X-linked Agammaglobulinemia", "XLA", "Primary Immune Deficiency", "CVID", "Common Variable Immunodeficiency", "Primary Antibody Deficiencies", "Secondary Hypogammaglobulinemia" ], "interventions": [], "intervention_types": [], "sponsor": "Duke University", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "6 Months", "maximum_age": null, "sex": "ALL", "summary": "6 Months and older" }, "enrollment_count": 100, "start_date": "2021-09-30", "completion_date": "2026-07-31", "has_results": false, "last_update_posted_date": "2025-06-03", "last_synced_at": "2026-09-08T11:31:18.226Z", "location_count": 3, "location_summary": "St. Petersburg, Florida • Chapel Hill, North Carolina • Durham, North Carolina", "locations": [ { "city": "St. Petersburg", "state": "Florida" }, { "city": "Chapel Hill", "state": "North Carolina" }, { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT05321407" }, { "nct_id": "NCT06585241", "title": "A Study to Investigate the Immunogenicity and Safety of mRNA COVID-19 Variant-containing Vaccine Formulations", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "SARS-CoV-2" ], "interventions": [ { "name": "mRNA-1273 Variant-containing Formulation", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "ModernaTX, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "6 Months", "maximum_age": null, "sex": "ALL", "summary": "6 Months and older" }, "enrollment_count": 1144, "start_date": "2024-09-09", "completion_date": "2026-12-31", "has_results": false, "last_update_posted_date": "2026-03-27", "last_synced_at": "2026-09-08T11:31:18.226Z", "location_count": 6, "location_summary": "Atlanta, Georgia • Decatur, Georgia • Baton Rouge, Louisiana + 3 more", "locations": [ { "city": "Atlanta", "state": "Georgia" }, { "city": "Decatur", "state": "Georgia" }, { "city": "Baton Rouge", "state": "Louisiana" }, { "city": "Gulfport", "state": "Mississippi" }, { "city": "Omaha", "state": "Nebraska" } ], "official_url": "https://clinicaltrials.gov/study/NCT06585241" }, { "nct_id": "NCT04649151", "title": "A Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273 Vaccine in Adolescents 12 to <18 Years Old to Prevent COVID-19", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "SARS-CoV-2" ], "interventions": [ { "name": "mRNA-1273", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "BIOLOGICAL" }, { "name": "mRNA-1273.222", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "ModernaTX, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "12 Years", "maximum_age": "18 Years", "sex": "ALL", "summary": "12 Years to 18 Years" }, "enrollment_count": 4328, "start_date": "2020-12-09", "completion_date": "2024-06-14", "has_results": true, "last_update_posted_date": "2025-09-15", "last_synced_at": "2026-09-08T11:31:18.226Z", "location_count": 48, "location_summary": "Banning, California • La Mesa, California • Lake Worth, Florida + 41 more", "locations": [ { "city": "Banning", "state": "California" }, { "city": "La Mesa", "state": "California" }, { "city": "Lake Worth", "state": "Florida" }, { "city": "Orlando", "state": "Florida" }, { "city": "Chamblee", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT04649151" }, { "nct_id": "NCT05212610", "title": "Assessing Safety of Coronavirus Infection (COVID-19) Messenger RNA (mRNA) Vaccine Administration in the Setting of a Previous Adverse Reaction", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "COVID-19", "Corona Virus Infection" ], "interventions": [ { "name": "Pfizer-BioNTech mRNA COVID-19 vaccine", "type": "BIOLOGICAL" }, { "name": "Moderna mRNA COVID-19 vaccine", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "University of Michigan", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 137, "start_date": "2022-03-21", "completion_date": "2025-03-07", "has_results": true, "last_update_posted_date": "2026-03-27", "last_synced_at": "2026-09-08T11:31:18.226Z", "location_count": 1, "location_summary": "Ann Arbor, Michigan", "locations": [ { "city": "Ann Arbor", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT05212610" }, { "nct_id": "NCT05280158", "title": "High-Dose Moderna mRNA-1273 Booster Study for Lung Transplant Recipients", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Lung Transplant Recipient", "SARS-CoV-2", "Immunosuppression" ], "interventions": [ { "name": "mRNA-1273 (Moderna COVID-19 vaccine)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of California, Los Angeles", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 19, "start_date": "2022-03-10", "completion_date": "2023-02-27", "has_results": true, "last_update_posted_date": "2025-03-26", "last_synced_at": "2026-09-08T11:31:18.226Z", "location_count": 1, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05280158" }, { "nct_id": "NCT04952402", "title": "SARS-CoV-2 Immune Responses After COVID-19 Therapy and Subsequent Vaccine", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Covid19", "SARS-CoV2 Infection" ], "interventions": [ { "name": "Study-provided Moderna mRNA-1273 COVID-19 vaccine", "type": "BIOLOGICAL" }, { "name": "Community-provided Moderna mRNA-1273 COVID-19 Vaccine", "type": "BIOLOGICAL" }, { "name": "Community-Provided Pfizer-BioNTech BNT162b2 COVID-19 Vaccine", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 43, "start_date": "2021-07-09", "completion_date": "2023-01-10", "has_results": true, "last_update_posted_date": "2023-05-24", "last_synced_at": "2026-09-08T11:31:18.226Z", "location_count": 6, "location_summary": "Los Angeles, California • San Diego, California • Chicago, Illinois + 3 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Chapel Hill", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT04952402" }, { "nct_id": "NCT04847050", "title": "A Trial of the Safety and Immunogenicity of the COVID-19 Vaccine (mRNA-1273) in Participants With Hematologic Malignancies and Various Regimens of Immunosuppression, and in Participants With Solid Tumors on PD1/PDL1 Inhibitor Therapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Solid Tumor Malignancy", "Hematologic Malignancy", "Leukemia", "Lymphoma", "Multiple Myeloma" ], "interventions": [ { "name": "Messenger ribonucleic acid (mRNA)-1273 Vaccine", "type": "BIOLOGICAL" }, { "name": "Messenger ribonucleic acid (mRNA)-1273 Vaccine Booster", "type": "BIOLOGICAL" }, { "name": "ECG", "type": "DIAGNOSTIC_TEST" }, { "name": "Antibiotics", "type": "OTHER" }, { "name": "Anti-viral agents", "type": "OTHER" }, { "name": "Anti-fungal agent", "type": "OTHER" }, { "name": "Anti-emetics", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "DIAGNOSTIC_TEST", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 19, "start_date": "2021-04-28", "completion_date": "2023-05-25", "has_results": true, "last_update_posted_date": "2024-08-27", "last_synced_at": "2026-09-08T11:31:18.226Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT04847050" }, { "nct_id": "NCT04927065", "title": "A Study to Evaluate the Immunogenicity and Safety of mRNA Vaccine Boosters for SARS-CoV-2 (COVID-19) Variants", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "SARS-CoV-2" ], "interventions": [ { "name": "mRNA-1273.211", "type": "BIOLOGICAL" }, { "name": "mRNA-1273", "type": "BIOLOGICAL" }, { "name": "mRNA-1273.617.2", "type": "BIOLOGICAL" }, { "name": "mRNA-1273.213", "type": "BIOLOGICAL" }, { "name": "mRNA-1273.529", "type": "BIOLOGICAL" }, { "name": "mRNA-1273.214", "type": "BIOLOGICAL" }, { "name": "mRNA-1273.222", "type": "BIOLOGICAL" }, { "name": "mRNA-1273.815", "type": "BIOLOGICAL" }, { "name": "mRNA-1273.231", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "ModernaTX, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 5161, "start_date": "2021-05-28", "completion_date": "2023-11-17", "has_results": true, "last_update_posted_date": "2025-02-28", "last_synced_at": "2026-09-08T11:31:18.226Z", "location_count": 23, "location_summary": "Sacramento, California • Hollywood, Florida • Jacksonville, Florida + 18 more", "locations": [ { "city": "Sacramento", "state": "California" }, { "city": "Hollywood", "state": "Florida" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Savannah", "state": "Georgia" }, { "city": "Sioux City", "state": "Iowa" } ], "official_url": "https://clinicaltrials.gov/study/NCT04927065" } ] }